A systematic review and meta-analysis evaluating the efficacy and safety of ghrelin agonists in diabetic gastroparesis found that ghrelin administration significantly improved overall gastroparesis symptoms, nausea, vomiting, early satiety, and abdominal pain compared to placebo, with no difference in adverse events [144]. This evidence concerns the gene GHRL and gastroparesis.